Home › Research › Prevention trials
The Gut Microbiota as a Mediator Linking the MIND Diet to Alzheimer’s Disease
Fatemeh Ramezani, Sina Sedaghat Herfeh, Emily Burke. Nutrients, 2026-04-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has emerged as a promising dietary pattern associated with reduced Alzheimer's disease (AD) risk, supported by growing evidence that both diet and the gut microbiota are modifiable contributors to disease development and progression. Observational studies have linked higher MIND diet adherence to lower AD incidence and slower cognitive decline, with certain comparative analyses reporting stronger associations with cognitive outcomes than those observed for the parent Mediterranean or DASH diets. Developed specifically to support cognitive health, the MIND diet emphasizes leafy green vegetables, berries, and olive oil while restricting butter, cheese, fried foods, sweets, and red meat. While these features suggest a biologically plausible basis for neuroprotection, the underlying mechanisms remain incompletely defined. The microbiota-gut-brain axis offers a potential mechanistic framework, as diet is a major determinant of gut microbiota composition and microbiota-derived metabolites that may influence brain function and AD-related pathways. However, direct evidence characterizing MIND diet-specific effects on the gut microbiota remains limited, with most mechanistic insights derived from related dietary patterns or individual dietary components. Accordingly, this review synthesizes evidence from these related dietary patterns and key MIND components to propose a conceptual framework linking the MIND diet, the gut microbiota, and AD risk, while highlighting priorities for future research.
What this study adds
Evidence grade: Low
This review discusses how the MIND diet may reduce Alzheimer's disease risk and proposes the gut microbiota as a possible link between diet and brain function. It notes that direct evidence on the MIND diet's effects on gut bacteria is limited, so the mechanism remains unproven.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ramezani, F., Herfeh, S. S., & Burke, E. (2026). The Gut Microbiota as a Mediator Linking the MIND Diet to Alzheimer’s Disease. Nutrients. https://doi.org/10.3390/nu18091445
Vancouver
Ramezani F, Herfeh SS, Burke E. The Gut Microbiota as a Mediator Linking the MIND Diet to Alzheimer’s Disease. Nutrients. 2026. doi:10.3390/nu18091445. PMID: 42124045.
BibTeX
@article{ramezani2026-42124045,
author = {Ramezani, Fatemeh and Herfeh, Sina Sedaghat and Burke, Emily},
title = {{The Gut Microbiota as a Mediator Linking the MIND Diet to Alzheimer’s Disease}},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18091445},
pmid = {42124045},
url = {https://doi.org/10.3390/nu18091445}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has emerged as a promising dietary pattern associated with reduced Alzheimer's disease (AD) risk, supported by growing evidence that both diet and the gut microbiota are modifiable contributors to disease development and progression.
Why it matters
This review discusses how the MIND diet may reduce Alzheimer's disease risk and proposes the gut microbiota as a possible link between diet and brain function. It notes that direct evidence on the MIND diet's effects on gut bacteria is limited, so the mechanism remains unproven.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 35 of the 96 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nutrients) |
| Journal's citation record | 3 / 4 | Nutrients: journal h-index 331 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 6.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Emily Burke holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Cedars-Sinai Medical Center: institution h-index 866 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42124045) |
| Free to read | 2 / 2 | Free to read |
| Points | 35 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 35 of the 96 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Prevention trials from nearby years
Also in Prevention trials
92 studies in the library are filed under Prevention trials with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention trials hub.